A multicenter, randomized, double-blind study was undertaken in 2342 infants to evaluate the safety and immunogenicity of 13 acellular and 2 whole cell pertussis vaccines combined with diphtheria and tetanus toxoids. Vaccines were administered to infants at 2, 4, and 6 months of age. Sera were obtained before the first vaccination (age 2 months) and 1 month after the third vaccination (age 7 months). All of the acellular vaccines produced significant increases in antibody for included antigens; mean antibody levels often exceeded those obtained with the reference whole cell vaccine. The vaccines were well-tolerated. All acellular vaccines were associated with significantly fewer adverse reactions than the control whole cell vaccine.
membrane protein), and two contained fimbrial antigens. Finally, there were two vaccines that we termed four-component: These contained PT, FHA, pertactin, and one or more fimbrial antigens.
Details of vaccine composition, manufacturers, and locations are shown in table 1. Antigen content varied substantially among the vaccines; the Biocine vaccines were unique in incorporating antigen produced by genetic engineering techniques. PT content varied from 50 J-lg for the Swiss Serum and Vaccine Institute (SSVI) preparation to 3.5 J-lg for the Lederle-Praxisl Takeda vaccine; most vaccines had 25 or 10 ug. FHA ranged from 35 to 2.5 ug, and only three vaccines contained <20 /-l,g. Pertactin and fimbrial protein concentrations similarly varied, although not over so wide a range. The vaccines also varied in content of diphtheria and tetanus toxoids.
Methods
Healthy children 6-12 weeks of age were recruited from private pediatric offices and vaccine clinics. Parents, patient care nurses, participating clinicians, and laboratory personnel were blinded to vaccine assignment. Subjects were vaccinated at 2, 4, and 6 months ofage. Serum specimens were obtained before the first and 1month after the last vaccination. IgG antibodies to PT, FHA, pertactin, and fimbrial proteins were measured by ELISAs at the Food and Drug Administration (FDA).
Local and systemic reactions were recorded by parents daily for 7 days and at 14 days. A nurse telephoned on the third day to review adverse reactions and again after the third week if the reaction form had not been returned. Adverse reactions were reviewed with the parents at each subsequent inoculation or phlebotomy. Finally, a long-term follow-up form was completed~1 year after the last vaccination.
Given 6375 analyzabIe reaction forms and 9 reaction categories, there were some 60,000 14-day reaction observation periods. For 97.9% of these observation periods, the reaction in question had reached its maximum by the third evening; there was no significant difference among the vaccines in the occurrence of reactions after the third evening. Thus, for each subject and reaction, we used the maximal extent of the reaction by the third evening after vaccination as a summary measure in order to simplify comparison of the individual acellular vaccines. 
Results
Serologic results are shown in table 2. A total of2342 infants were enrolled; analyzable paired serum specimens were available for 1942. There was no difference among the study groups in preimmunization geometric mean antibody concentrations or titers (GMTs) for any measured antibody.
Antibody concentrations varied substantially among the vaccine groups. All vaccines produced statistically significant rises in antibody to PT. However, postimmunization GMTs differed significantly among the acellular vaccine groups and did not appear to correlate with the PT antigen content of the vaccines. The Biocine one-component vaccine stimulated significantly higher levels of antibody to PT than any other vaccine; GMTs for the Connaught Biken two-component, SmithKline Beecham (SKB) two-component, Biocine three-component, and SSVI groups also were significantly higher than for the whole cell control group. The Lederle-Praxis/Takeda vaccine stimulated significantly lower levels of antibody to PT than any other vaccine; GMTs for the Porton three-component, Connaught three-and four-component, and Lederle-Praxis three-component groups were also significantly lower than for the whole cell control group. Despite these lower GMTs, all acellular vaccines except the Lederle-Praxis/Takeda preparation produced higher rates of seroconversion to PT than did the whole cell control vaccine.
Whole cell recipients were 23 times more likely to lack antibody to PT after vaccination: 12.9% of whole cell recipients versus 0.6% of acellular vaccine recipients had postimmunization PT antibody levels below the lower limit of detection.
Antibody responses to FHA. The ability of the acellular vaccines containing FHA to stimulate antibody varied substantially, but all produced postimmunization titers significantly higher than those in the group receiving the whole cell control vaccine. Antibody responses generally correlated with quantity of FHA per dose, with the exception of the Lederle-Praxis/ Takeda and Porton vaccines, which produced lower levels of antibody than did some vaccines containing less FHA. The Michigan vaccine stimulated significantly higher levels of antibody to FHA than any other vaccine.
Antibody responses to pertactin. All of the acellular vaccines containing pertactin produced significant rises in antibody, the magnitude of which correlated directly with the quantity of pertactin incorporated. Postimmunization pertactin GMTs were significantly higher with the SKB three-component vaccine than with any other; the Lederle-Praxis three-component and Connaught four-component vaccines also were more immunogenic than whole cell vaccine. The pertactin antibody responses to the Biocine three-component and Lederle-Praxis/ Takeda vaccines did not differ from those seen with the control whole cell vaccine.
Antibody responses to fimbriae. With one exception, postimmunization levels of antibody to fimbriae correlated directly with the reported content of each vaccine. The Lederle-Praxis threecomponent vaccine was not known to contain fimbriae but produced a 4-fold rise in antibody among 40% of recipients, in marked contrast to the results with the other acellular vaccines not containing fimbriae. Of the four vaccines reported to contain fimbriae, the Porton preparation produced significantly more fimbrial antibody than did whole cell vaccine, and the Lederle-Praxis/ Takeda vaccine produced significantly less. Levels of agglutinating antibody correlated strongly with content of fimbrial antigen and less strongly with content of pertactin.
Conjugate Haemophilus injiuenzae type B (Hib) vaccines were licensed midway through our study and were then incorporated into our protocol. Analysis showed no effect of Hib vaccination on pertussis antibody levels or adverse reactions. We did not evaluate Hib antibody results.
Adverse reactions. In total, 23 subjects were withdrawn from the study due to adverse reactions (most for prolonged, inconsolable, or high-pitched cry), representing 2.5% of whole cell and 0.8% of acellular recipients; the rates of withdrawal for adverse reactions, intercurrent illness, or failure to return did not differ among the acellular vaccines.
Twenty-one subjects experienced unplanned hospitalization or another unusual or severe health event between the time of enrollment and final phlebotomy. Three of these events occurred in close proximity to receipt of vaccine: a seizure, an episode of urticaria, and an episode of listlessness, fever, and vomiting. The children in the latter two events continued in the study without further complications. The remaining 20 unusual events, which did not appear to be vaccine-related, included I sudden infant death, I near death, and seizures at 35, 42, and 21 days after vaccination. One subject developed culture-proven pertussis 14 days after the first inoculation. For every acellular vaccine, every monitored adverse reaction except vomiting was significantly less frequent and, where pertinent, less severe compared with reactions in the whole cell vaccine group. Figures 2-5 show rates of various adverse reactions among recipients of acellular vaccine (as a group) and of control whole cell vaccine.
All of the adverse reactions showed similar patterns over time after each inoculation. As illustrated for fever in figure 2 , a substantial proportion of subjects developed adverse reactions as soon as 3 h after inoculation; adverse reactions were maximal on the first or second evening, and the frequency and severity of adverse reactions declined thereafter. Most reactions began to decline from their peak frequency and severity somewhat sooner among whole cell vaccine recipients than among those receiving acellular preparations. .101,1-102,OF (38.4 -38JJ"C)
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For both acellular and whole cell vaccine recipients, fever significantly increased in prevalence and severity with successive inoculations. The frequency and severity of fever did not significantly differ among the acellular pertussis vaccines; all were associated with significantly less fever than was whole cell vaccine. Only 5 subjects experienced fever~39.7°C; of these, 3 became afebrile after vaccination and then developed new fever with symptoms of an intercurrent illness.
Redness also increased significantly with successive inoculations (figure 3), although the trend was less pronounced. The pattern was similar for swelling. Acellular vaccines differed significantly in redness produced: Lederle-Praxis three-component recipients experienced redness at about half the overall rate of that of all acellular vaccine recipients. Swelling also differed significantly among the acellular vaccine groups, again due to the low rate among the Lederle-Praxis vaccine recipients.
There was no significant change from inoculation to inoculation in severity of pain, fussiness, anorexia, vomiting, or use of antipyretics; drowsiness after vaccination decreased following subsequent vaccinations. • 11-20mm
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• 41-50mm >50mm 5 6 7 14 recipients, and none differed significantly among the various acellular vaccine groups. The rate of vomiting did not differ significantly between whole cell and the acellular vaccines as a group but differed significantly among the acellular vaccines due to an elevated rate with the Connaught three-component vaccme.
Long-term follow-up data obtained a mean of 19 months after enrollment were available for 82% of the enrollees. The rates of hospitalization, developmental delay, seizures, other neurologic problems, failure to thrive, prolonged cough, and other serious infections did not differ significantly among vaccinees given different preparations. never were noted to have pain, and overall only 6.9% had moderate or severe pain compared with 40% of whole cell vaccine recipients. However, there was substantial variation among the acellular vaccines in the frequency and severity of pain induced. The Biocine three-component vaccine was associated with a low prevalence of pain overall and at each inoculation; the pattern by inoculation was quite variable for the other vaccines. Figure 5 shows the incidence of fussiness, categorized as irritable, crying, or inconsolable. Whole cell vaccine was associated with .-...,2.5 times more moderate or severe fussiness than the acellular vaccines as a group; the prevalence of fussiness did not significantly differ among the acellular vaccines.
Antipyretic use, drowsiness, and anorexia were significantly more common among whole cell than among acellular vaccine After the completion of our study, the NIAID Pertussis Task Force reviewed our provisional data and the FDA analyses of the vaccines' laboratory characteristics and made a series of recommendations based on reactogenicity, immunogenicity, and purity. On the basis of these recommendations and other considerations, Swedish investigators included SKB two-component and Connaught four-component vaccines in an efficacy study. Italian investigators have evaluated SKB and Biocine three-component vaccines. Other efficacy trials of selected acellular vaccines are in progress or were completed recently in Germany, Senegal, and Sweden with the support of other sponsors. Results from many of these studies have been reported and were recently summarized [3] . fewer and less severe adverse reactions than the whole cell vaccine. Most induced levels of antibody against included antigens that equaled or exceeded that of the control Lederle-Praxis whole cell vaccine.
Particularly for PT, immunogenicity appeared to depend not only on antigen concentration but also on other factors, possibly including antigen derivation and formulation. For the other antigens, antibody results generally paralleled the quantity of antigen included. Although no multicomponent vaccine was most or least immunogenic with respect to all of its compo- 
